C5 and myasthenia gravis: While Ota et al. [36] and Shiga et al. [39] observed marked increases in C3a and C5a and Fadul et al. [37] reported slight increases in C3a in the treatment of patients with different (neuroimmunological) diseases, which confirms the observations of the present study, Grob et al. [35] observed an increase in C5a but a decrease in C3a in patients with myasthenia gravis, and Palm et al. [34] did not observe an influence on the C3a levels in an in vitro setup.